Arcus Biosciences Company Insiders
RCUS Stock | USD 8.94 0.13 1.43% |
Slightly above 75% of Arcus Biosciences' corporate insiders are selling. The analysis of the overall insider sentiment regarding Arcus Biosciences suggests that many insiders are alarmed. Arcus Biosciences employs about 627 people. The company is managed by 31 executives with a total tenure of roughly 106 years, averaging almost 3.0 years of service per executive, having 20.23 employees per reported executive.
Terry Rosen Chairman Chairman of the Board, Chief Executive Officer, Co-Founder |
Juan Jaen President President, Co-Founder, Director |
Insider Sentiment 25
Mostly Selling
Selling | Buying |
Latest Trades
2025-02-27 | Yasunori Kaneko | Acquired 20000 @ 10.06 | View | ||
2024-12-31 | Robert C Goeltz II | Disposed 3594 @ 15 | View | ||
2024-12-02 | Alexander Azoy | Disposed 201 @ 15.32 | View | ||
2024-03-27 | Jennifer Jarrett | Disposed 11551 @ 17.55 | View |
Monitoring Arcus Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Arcus |
Arcus Biosciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Arcus Biosciences' future performance. Based on our forecasts, it is anticipated that Arcus will maintain a workforce of slightly above 630 employees by April 2025.Arcus Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.1726) % which means that it has lost $0.1726 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5977) %, meaning that it created substantial loss on money invested by shareholders. Arcus Biosciences' management efficiency ratios could be used to measure how well Arcus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.26 in 2025. Return On Capital Employed is likely to drop to -0.37 in 2025. At this time, Arcus Biosciences' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 204.6 M in 2025, whereas Other Assets are likely to drop slightly above 8.5 M in 2025.Common Stock Shares Outstanding is likely to drop to about 62.4 M in 2025. Net Loss is likely to gain to about (228.3 M) in 2025
Arcus Biosciences Workforce Comparison
Arcus Biosciences is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,782. Arcus Biosciences retains roughly 627 in number of employees claiming about 11% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.96) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.96. Arcus Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcus Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcus Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Arcus Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 3.5 | 14 | 4 | 226,800 | 36,491 |
2024-03-01 | 1.6 | 16 | 10 | 16,570,045 | 119,636 |
2023-12-01 | 0.0588 | 1 | 17 | 448.00 | 102,684 |
2023-06-01 | 1.875 | 15 | 8 | 1,194,100 | 102,027 |
2023-03-01 | 1.0 | 12 | 12 | 1,514,700 | 116,996 |
2022-09-01 | 3.0 | 3 | 1 | 382,500 | 0.00 |
2022-06-01 | 1.625 | 13 | 8 | 154,900 | 13,816 |
2022-03-01 | 3.0 | 9 | 3 | 570,500 | 680,691 |
2021-09-01 | 0.2857 | 2 | 7 | 26,400 | 47,500 |
2021-06-01 | 0.7647 | 13 | 17 | 106,733 | 37,676 |
2021-03-01 | 4.3333 | 13 | 3 | 6,837,138 | 322,688 |
2020-12-01 | 0.3846 | 5 | 13 | 1,125,500 | 2,816,117 |
2020-09-01 | 1.75 | 7 | 4 | 303,905 | 0.00 |
2020-06-01 | 5.3333 | 16 | 3 | 390,000 | 40,000 |
2019-12-01 | 4.0 | 4 | 1 | 100,400 | 0.00 |
2018-12-01 | 2.0 | 2 | 1 | 45,000 | 8,000 |
2018-03-01 | 0.5806 | 18 | 31 | 20,759,869 | 24,877,084 |
Arcus Biosciences Notable Stakeholders
An Arcus Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Arcus Biosciences often face trade-offs trying to please all of them. Arcus Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Arcus Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Terry Rosen | Chairman of the Board, Chief Executive Officer, Co-Founder | Profile | |
Juan Jaen | President, Co-Founder, Director | Profile | |
Robert Goeltz | Chief Financial Officer, Principal Financial and Accounting Officer | Profile | |
Patrick Machado | Independent Director | Profile | |
Antoni Ribas | Independent Director | Profile | |
Andrew Perlman | Independent Director | Profile | |
Yasunori Kaneko | Lead Independent Director | Profile | |
David Lacey | Independent Director | Profile | |
Kathryn Falberg | Independent Director | Profile | |
Alexander Azoy | VP Officer | Profile | |
Alexander CPA | VP Officer | Profile | |
Jennifer MBA | Chief Officer | Profile | |
Nicole Lambert | Director | Profile | |
Jason Barker | Vice President - Finance | Profile | |
Jennifer Jarrett | Chief Business and Financial Officer | Profile | |
Eric Matthews | Chief Officer | Profile | |
Michael Quigley | Director | Profile | |
Linda Higgins | Director | Profile | |
Holli Kolkey | Vice Communications | Profile | |
Carolyn JD | General Secretary | Profile | |
Katherine Bock | Vice Strategy | Profile | |
Robert II | Principal CFO | Profile | |
Eric Hoefer | Chief Commercial Officer & Head of Business Development | Profile | |
Stephen Young | Senior Biology | Profile | |
Jonathan Yingling | Chief Officer | Profile | |
Yvonne Gehring | Senior Operations | Profile | |
Carolyn Tang | General Counsel | Profile | |
Merdad Parsey | Director | Profile | |
Christopher Garcia | CoFounder Board | Profile | |
William Grossman | Chief Medical Officer | Profile | |
Pia Eaves | Vice Strategy | Profile |
About Arcus Biosciences Management Performance
The success or failure of an entity such as Arcus Biosciences often depends on how effective the management is. Arcus Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arcus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arcus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.25) | (0.26) | |
Return On Capital Employed | (0.36) | (0.37) | |
Return On Assets | (0.25) | (0.26) | |
Return On Equity | (0.58) | (0.61) |
Please note, the imprecision that can be found in Arcus Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arcus Biosciences. Check Arcus Biosciences' Beneish M Score to see the likelihood of Arcus Biosciences' management manipulating its earnings.
Arcus Biosciences Workforce Analysis
Traditionally, organizations such as Arcus Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Arcus Biosciences within its industry.Arcus Biosciences Manpower Efficiency
Return on Arcus Biosciences Manpower
Revenue Per Employee | 411.5K | |
Revenue Per Executive | 8.3M | |
Net Loss Per Employee | 451.4K | |
Net Loss Per Executive | 9.1M | |
Working Capital Per Employee | 1.3M | |
Working Capital Per Executive | 25.5M |
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.